Pharmafile Logo
Pharmafocus logo
Advanced Search

wet AMD

Showing 15 posts of 19 posts found.

Bayer image

Novartis and Bayer seek to oppose High Court ruling over NHS decision to use cheaper drug

October 16, 2018
Manufacturing and Production Bayer, CCG, NHS, Novartis, avastin, wet AMD

Swiss multinational Novartis have joined German pharma firm Bayer in appealing a High Court ruling over 12 NHS clinical commissioning …

News
regeneron

Regeneron and Ocular Therapeutix to collaborate in potential $315 million deal

October 14, 2016
Medical Communications Bayer, Eyelea, Ocular Therapeutix, Regeneron Pharmaceuticals, wet AMD

Regeneron Pharmaceuticals and Ocular Therapeutix have entered into a deal that will see them collaborate to develop a sustained release …

News
Avastin image

EU nod for Roche cancer drug and chemotherapy

April 8, 2015
Sales and Marketing Cancer, Roche, avastin, bevacizumab, cervical, chemotherapy, wet AMD

The European Commission has approved Roche’s Avastin in combination with standard chemotherapy for women with advanced cervical cancer.  Avastin (bevacizumab) …

News
Lucentis image

Novartis accused of Lucentis ‘campaign’ against Avastin

April 2, 2015
Sales and Marketing Lucentis, NHS, Novartis, avastin, bevacizumab, ranibizumab, wet AMD

Novartis “embarked on a campaign to undermine and divert attention” from a cheap drug for vision loss and maintain the …

News
Avastin image

Doctors appeal to prescribe Avastin off-label

February 25, 2015
Sales and Marketing Lucentis, NHS, NICE, Novartis, Roche, bevacizumab, wet AMD

NHS Clinical Commissioners have called for the removal of barriers preventing CCGs from prescribing Roche’s Avastin to treat wet age-related …

News

France ‘to approve’ Avastin use

July 3, 2014
Sales and Marketing AMD, France, Lucentis, Novartis, Roche, avastin, off label, off-label, wet AMD

The French government is planning to allow Roche’s cancer drug Avastin to be prescribed off-label to treat wet age-related macular …

News
roche_logo_shadow

Roche/Novartis offices raided over anti-competitive activities

April 11, 2014
Sales and Marketing Lucentis, Novartis, Roche, SHIP Cluster, avastin, wet AMD

French competition authorities are investigating Roche and Novartis in connection with their marketing of Lucentis for wet age-related macular degeneration …

News
Bayer image

Bayer and Regeneron to co-develop wet AMD antibody

January 14, 2014
Research and Development, Sales and Marketing Bayer, Eylea, Regeneron, pdgfr-beta, wet AMD

Bayer and Regeneron are co-developing an antibody to the Platelet Derived Growth Factor Receptor Beta (PDGFR-beta) as a combination therapy …

News
eylea-product-box-md

Eylea receives new European approval

August 30, 2013
Research and Development, Sales and Marketing Bayer, CRVO, Eylea, Lucentis, Novartis, wet AMD

News
Eylea image

Eylea approval for wet AMD

November 29, 2012
Sales and Marketing Bayer, Eylea, Lucentis, Novartis, avastin, wet AMD

Bayer HealthCare’s Eylea has been appoved in Europe for the treatment of neovascular age-related macular degeneration (wet AMD). The eye …

News
novartis_window

New Avastin data could be bad news for Lucentis

August 14, 2012
Research and Development, Sales and Marketing DMO, Lucentis, Novartis, Roche, avastin, off label, off-label, wet AMD

The day after Novartis gained a new US licence for Lucentis to treat diabetic macular oedema, new data was published …

News
Lucentis image

Lucentis gains new licence in the US

August 13, 2012
Sales and Marketing Eylea, FDA, Lucentis, approval, avastin, wet AMD

Roche’s eye drug Lucentis has gained a new licence in the US to treat diabetic macular oedema. The FDA has …

News
screen_shot_2012-04-27_at_10

Novartis right to challenge NHS on Avastin use – ABPI chief

April 27, 2012
Sales and Marketing ABPI, Lucentis, Whitehead, avastin, wet AMD

The ABPI has declared its support for Novartis in its legal challenge against off-label prescribing in England.The pharma company is …

News
Lucentis image

Charity challenges government on Avastin for wet AMD

April 24, 2012
Sales and Marketing Lucentis, Novartis, Roche, avastin, off label, off-label, wet AMD

A leading patient group has called on the government to get to grips with the issue of off-label prescribing, as …

News

Bayer eye drug succeeds in long-term study

February 21, 2012
Research and Development, Sales and Marketing Bayer, Lucentis, aflibercept, wet AMD

Bayer’s eye drug aflibercept has succeeded in a long-term study in patients with a common eye condition.  The Phase III …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025